Showing 81 - 95 results of 95 for search '"pharmaceutical company"', query time: 0.06s Refine Results
  1. 81

    COVID-19 CONSPIRACISM IN THE AGE OF POST-TRUTH by Ömer Ersin Kahraman

    Published 2022-12-01
    “…Consequently, this period has also witnessed the diffusion of conspiracy theories varying from accusations which consider the rapid propagation of the virus as a plot of states and big pharmaceutical companies to allegations which presume the pandemic as a hoax to implement new communication technologies like 5G. …”
    Get full text
    Article
  2. 82

    Kleinia (Asteraceae): comprehensive review of ethnomedicinal uses, phytochemical profiles, ethnopharmacological applications, and toxicological insights by Bantayehu Addis Tegegne, Tesfa Begashaw, Wubetu Yihunie Belay, Mengistie Kassahun Tariku, Tirsit Ketsela Zeleke, Mohammed Jemal, Mamaru Getinet, Agumas Alemu Alehegn, Abebe Dagne

    Published 2025-01-01
    “…It encourages global pharmaceutical companies and academic institutions to conduct thorough investigations of the genus Kleinia to uncover new therapeutic possibilities.…”
    Get full text
    Article
  3. 83

    Transformations of Medical and Vaccine Diplomacies in the COVID-19 Era by I. I. Arsentyeva

    Published 2022-11-01
    “…The article examines the current policy of China, as it has achieved the most notable success in medical services export, primarily to developing countries, and Chinese pharmaceutical companies play a prominent role in the global vaccine market. …”
    Get full text
    Article
  4. 84

    Young TPI: empowering animal-free science among the next- generation of scientists by Marta G. Valverde, Marta G. Valverde, Fatima Zohra Abarkan, Fatima Zohra Abarkan, Rebecca Van Eijden, Rebecca Van Eijden, Julia M. L. Menon, Julia M. L. Menon, Nikolas Gaio, Nikolas Gaio, Aarti Ramchandran, Aarti Ramchandran, Victoria C. De Leeuw, Victoria C. De Leeuw

    Published 2025-01-01
    “…Boasting over 270 members spanning Dutch 49 institutions, including biotechnology startups and pharmaceutical companies and universities, Young TPI harnesses the diverse expertise of its members to propel a sustainable, future-proof transition and to promote a continuous dialogue with a wide range of stakeholders. …”
    Get full text
    Article
  5. 85

    Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines by Albrecht Jahn, Rosa Jahn, Anna Volodina

    Published 2024-05-01
    “…This study explored whether similar policies could improve access to medicines in other countries.Methods We conducted 46 interviews with representatives from healthcare practice, patient organisations and health authorities from six countries (Australia, Brazil, Canada, Kenya, Russia and South Africa) as well as multinational pharmaceutical companies exploring their views regarding access barriers to paediatric medicines. …”
    Get full text
    Article
  6. 86

    Impact of the Clinical Trials Act 2018 on clinical trial activity in Japan from 2018 to 2020: a retrospective database study using new and conventional Japanese registries by Hiroyuki Taruno, Mari S Oba, Osamu Takizawa, Kayoko Kikuchi, Kazuaki Matsui, Mayumi Shikano

    Published 2022-07-01
    “…The temporal trends in clinical trial activity after CTA enactment were examined.Results A total of 577 CTA-compliant specified clinical trials (ie, studies funded by pharmaceutical companies or studies evaluating the efficacy and safety of off-label drugs or devices in humans) were registered in the jRCT. …”
    Get full text
    Article
  7. 87

    Integrating knowledge management with smart technologies in public pharmaceutical organizations by Muhanad Mahmoud, Talaat Shma, Adel Aziz, Abdelrehim Awad

    Published 2025-01-01
    “…Using a descriptive-analytical approach, the study targeted employees from five public pharmaceutical companies in Cairo Governorate, including Memphis Pharmaceuticals, Arab Pharmaceuticals, Cairo Pharmaceuticals, Nile Pharmaceuticals, and EIPICO. …”
    Get full text
    Article
  8. 88

    The role of Pharmaceutical Marketing in Prescribing Decisions in a Developing Country: A Comprehensive Study Exploiting Theory of Planned Behaviour by Mahmoud Al-Areefi, Mohamed Izham Mohamed Ibrahim, Abubakr Abdelraouf Alfadl

    Published 2024-11-01
    “…Conclusion: This research clarified the role played by pharmaceutical companies to influence prescribing decisions of physicians. …”
    Get full text
    Article
  9. 89

    Readability and understandability of clinical research patient information leaflets and consent forms in Ireland and the UK: a retrospective quantitative analysis by Peter Doran, Eilish McAuliffe, Lydia O'Sullivan, Prasanth Sukumar, Rachel Crowley

    Published 2020-09-01
    “…The second aim was to compare these findings with best practice guidelines.Design Retrospective, quantitative analysis of clinical research PILs/ICFs provided by academic institutions, pharmaceutical companies and investigators.Setting PILs/ICFs which had received Research Ethics Committee approval in the last 5 years were collected from Ireland and the UK.Intervention Not applicable.Main outcome measures PILs/ICFs were evaluated against seven validated readability criteria (Flesch Reading Ease, Flesh Kincaid Grade Level, Simplified Measure of Gobbledegook, Gunning Fog, Fry, Raygor and New Dale Chall). …”
    Get full text
    Article
  10. 90

    Ten proposed measures to improve vaccination: Health care providers’ perspectives on promoting the vaccination intake of children with special healthcare needs in China by Xiang Guo, Tianxing Feng, Meiyi Chen, Xuran Zhao, Xiangshi Wang, Yanling Ge, Zhonglin Wang, Zhuoying Huang, Mei Zeng

    Published 2025-01-01
    “…The interview guide explored attitudes towards and suggestions for establishing immunisation advisory clinics and referral networks, updating immunisation guidance documents and vaccine package inserts and strengthening the education of vaccination providers.Results 21 representative healthcare providers were interviewed. 10 measures were proposed to promote routine immunisation for children with special needs: (1) using immunisation advisory clinics to provide vaccination services for CSHCN; (2) establishing a referral network and specifying which cases necessitate referral to advisory clinics; (3) using an interconnected information system to identify, document and follow-up the CSHCN; (4) supporting high-quality clinical research to update immunisation protocols; (5) providing clear and definite immunisation recommendations to parents of eligible CSHCN; (6) seeking immunisation advice from specialised professionals to enhance primary care capability; (7) creating quality improvement programmes; (8) considering immunisation status a mandatory assessment during specialist visits; (9) supporting off-label use of vaccines legally and (10) encouraging pharmaceutical companies to update vaccine package inserts.Conclusion Vaccine uptake among CSHCN in China is suboptimal, highlighting the need for a referral network and a standard immunisation protocol. …”
    Get full text
    Article
  11. 91

    Understanding trends in osteoporosis drug prescribing: implications for reducing futile biomedical research by Jonathan R. Guillemot, Jonathan R. Guillemot, John W. Abraham, Anthea Tinker

    Published 2025-01-01
    “…Trust dynamics between physicians, pharmaceutical companies, and health authorities influenced prescribing trends, with variations in reliance on standardized protocols and collaborative decision-making observed between England and France.DiscussionUnderstanding trends in osteoporosis drug prescribing is crucial for optimizing healthcare policy and practice. …”
    Get full text
    Article
  12. 92
  13. 93
  14. 94

    Trends for Clinical Trials on Medicinal Products for Neurological Disorders in Lithuania and Europe by Emilijus Žilinskas, Arūnas Vaitkevičius

    Published 2024-03-01
    “…The majority of the trials (72.18%) were sponsored by commercial pharmaceutical companies. Most trials (31.73%) were registered as phase I trials. …”
    Get full text
    Article
  15. 95

    Journal of Health and Social Sciences: A reputable, DOAJ-indexed, free, open access journal by Francesco Chirico

    Published 2019-03-01
    “…In addition, JHSS has not received any economic support from public or economic institutions or pharmaceutical companies. JHSS is pure because it is free of any political or economic pressures; it is propelled by highly passionate, enthusiastic, competent contributing researchers and their tireless work. …”
    Get full text
    Article